Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2385-2393

  Hainsworth, John D ^a   Erland, Joan B ^a   Kalman, Leonard A ^a   Schreeder, Marshall T ^a   Greco, F Anthony ^a  

^a CENTENNIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0031004065     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2385     Document Type: Article

References (30)

1. Goldberg PM, Smith FP, Ueno W, et al: Fluorouracil, Adriamycin, mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 4:395-399, 1986
2. VanderGaast A, Verweij J, Planting AST, et al: 5-Fluorouracil, doxorubicin, and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 24:765-768, 1988
3. Anderson H, Thatcher N, Rankin E, et al: VAC (vincristine, Adriamycin and cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. Eur J Cancer Clin Oncol 19:49-52, 1983
4. Eagan RT, Thermean TM, Rubin J, et al: Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am J Clin Oncol 10:82-85, 1987
5. Lenzi R, Abbruzzese J, Amato R, et al: Cisplatin, 5-FU, and folinic acid for the treatment of carcinoma of unknown primary: A phase II study. Proc Am Soc Clin Oncol 10:1055, 1991 (abstr)
6. Greco FA, Vaughn WK, Hainsworth JD: Advanced poorly differentiated carcinoma of unknown primary site: Recognition of a treatable syndrome. Ann Intern Med 104:547-551, 1986
7. Hainsworth JD, Johnson DH, Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 10:912-922, 1992
8. VanderGaast A, Verweij J, Henzen-Logmans SC, et al: Carcinoma of unknown primary. Identification of a treatable subset. Ann Oncol 1:119-123, 1990
9. Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Referral Center 9013. J Clin Oncol 11:2405-2410, 1993
10. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
11. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer. J Clin Oncol 13:1609-1614, 1995
12. Ajani JA, Ilson DH, Daugherty K, et al: Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091, 1994
13. Forestiere AA, Neuberg D, Taylor SG, et al: Phase II evaluation of Taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group trial. J Natl Cancer Inst Monogr 15:181-186, 1993
14. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994
15. Hainsworth JD, Stroup SL, Greco FA: Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer. Cancer 77:2458-2463, 1996
16. Hainsworth JD, Stroup SL, Gray JR, et al: Paclitaxel (1-hour infusion), carboplatin, and extended schedule etoposide in small cell lung cancer: A second generation phase II study. Proc Am Soc Clin Oncol 15:400, 1996 (abstr)
17. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-38, 1976
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Hainsworth JD, Johnson DH, Greco FA: Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity. Ann Intern Med 109:364-372, 1988
20. Milliken ST, Tattersall MHN, Woods RL, et al: Metastatic adenocarcinoma of unknown primary site: A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 23:1645-1650, 1987
21. Kambhu I, Kelsen D, Niedzwiecki D, et al: Phase II trial of mitomycin-C, vindesine, and Adriamycin and predictive variables in the treatment of patients with adenocarcinoma of unknown primary site. Proc Am Assoc Cancer Res 27:734, 1986 (abstr)
22. Alberts AS, Falkson G, Falkson HC, et al: Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients. Med Pediatr Oncol 17:188-196, 1989
23. Bedikian AY, Valdivieso M, Bodey GP, et al: Sequential chemotherapy for adenocarcinoma of unknown primary. Am J Clin Oncol 6:219-222, 1983
24. Jadeja J, Legha S, Burgess M, et al: Combination chemotherapy with 5-FU, Adriamycin, cyclophosphamide, and cis-platinum in the treatment of adenocarcinoma of unknown primary and undifferentiated carcinoma. Proc Am Soc Clin Oncol 2:926, 1983 (abstr)
25. Pasterz R, Savoraj N, Burgess M: Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol 4:1652-1661, 1986
26. Becouarn Y, Brunet R, Barbe-Gaston C: Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer Clin Oncol 25:861-868, 1989
27. Raber MN, Faintuch S, Abbruzzese JL, et al: Continuous infusion 5-fluorouracil, etoposide, and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol 2:519-522, 1991
28. deCampos ES, Menasce LP, Radford J, et al: Metastatic carcinoma of uncertain primary site: A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE). Cancer 73:470-481, 1994
29. Abbruzzese JL, Abbruzzese MC, Hess KR, et al: Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272-1284, 1994
30. Hainsworth JD, Raefsky EL, Greco FA: Paclitaxel administered by a one hour infusion: A phase I/II trial comparing two schedules. Cancer J Sci Am 1:281-287, 1995